The effect of insulin degludec on risk of symptomatic nocturnal hypoglycaemia in adults with type 1 diabetes and high risk of nocturnal severe hypoglycaemia (the HypoDeg trial): study rationale and design

Rikke Mette Agesen; Amra Ciric Alibegovic; Henrik Ullits Andersen; Henning Beck-Nielsen; Peter Gustenhoff; Troels Krarup Hansen; Christoffer Hedetoft; Tonny Jensen; Claus Bogh Juhl; Susanne Søgaard Lerche; Kirsten Nørgaard; Hans-Henrik Parving; Lise Tarnow; Birger Thorsteinsson; Ulrik Pedersen-Bjergaard

doi:10.1186/s12902-019-0408-x

The effect of insulin degludec on risk of symptomatic nocturnal hypoglycaemia in adults with type 1 diabetes and high risk of nocturnal severe hypoglycaemia (the HypoDeg trial): study rationale and design

BMC Endocrine Disorders ◽

10.1186/s12902-019-0408-x ◽

2019 ◽

Vol 19 (1) ◽

Cited By ~ 1

Author(s):

Rikke Mette Agesen ◽

Amra Ciric Alibegovic ◽

Henrik Ullits Andersen ◽

Henning Beck-Nielsen ◽

Peter Gustenhoff ◽

...

Keyword(s):

Type 1 Diabetes ◽

High Risk ◽

Severe Hypoglycaemia ◽

Insulin Degludec ◽

Nocturnal Hypoglycaemia

Download Full-text

Comparison of treatment with insulin degludec and glargine U100 in patients with type 1 diabetes prone to nocturnal severe hypoglycaemia: The HypoDeg randomised, controlled, open‐label, cross‐over trial

Diabetes Obesity and Metabolism ◽

10.1111/dom.14574 ◽

2021 ◽

Author(s):

Ulrik Pedersen‐Bjergaard ◽

Rikke M. Agesen ◽

Julie M. B. Brøsen ◽

Amra C. Alibegovic ◽

Henrik U. Andersen ◽

...

Keyword(s):

Type 1 Diabetes ◽

Severe Hypoglycaemia ◽

Insulin Degludec ◽

Open Label ◽

Randomised Controlled

Download Full-text

Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal–bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN ® Basal–Bolus Type 1): 2‐year results of a randomized clinical trial

Diabetic Medicine ◽

10.1111/dme.12243 ◽

2013 ◽

Vol 30 (11) ◽

pp. 1293-1297 ◽

Cited By ~ 65

Author(s):

B. W. Bode ◽

J. B. Buse ◽

M. Fisher ◽

S. K. Garg ◽

M. Marre ◽

...

Keyword(s):

Clinical Trial ◽

Type 1 Diabetes ◽

Glycaemic Control ◽

Insulin Glargine ◽

Insulin Aspart ◽

Insulin Degludec ◽

Nocturnal Hypoglycaemia ◽

Mealtime Insulin ◽

Basal Bolus

Download Full-text

Comparison of Treatment with Insulin Degludec and Glargine U100 in Patients with Type 1 Diabetes Prone to Nocturnal Severe Hypoglycaemia (HypoDeg): A Prospective, Randomized, Open-Label, Crossover Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3690928 ◽

2020 ◽

Author(s):

Rikke Agesen ◽

Amra Ciric Alibegovic ◽

Henrik Ullits Andersen ◽

Henning Beck-Nielsen ◽

Peter Gustenhoff ◽

...

Keyword(s):

Type 1 Diabetes ◽

Crossover Trial ◽

Severe Hypoglycaemia ◽

Insulin Degludec ◽

Open Label

Download Full-text

Comparison of insulin degludec and glargine U100 in type 1 diabetes patients prone to severe nocturnal hypoglycaemia

10.26226/morressier.5d9b6231ea541d6ca8493f78 ◽

2019 ◽

Author(s):

Rikke Agesen

Keyword(s):

Type 1 Diabetes ◽

Insulin Degludec ◽

Nocturnal Hypoglycaemia ◽

Diabetes Patients

Download Full-text

1544-P: High Risk of Adverse Drug Reaction (ADR) in Older Adults with Type 1 Diabetes (T1D)

Diabetes ◽

10.2337/db19-1544-p ◽

2019 ◽

Vol 68 (Supplement 1) ◽

pp. 1544-P ◽

Cited By ~ 3

Author(s):

ELENA TOSCHI ◽

CHRISTINE SLYNE ◽

ASTRID ATAKOV-CASTILLO ◽

KAYLA SIFRE ◽

ALYSSA B. DUFOUR ◽

...

Keyword(s):

Older Adults ◽

Adverse Drug Reaction ◽

Type 1 Diabetes ◽

Drug Reaction ◽

High Risk

Download Full-text

344-OR: Slowed Metabolic Decline after Oral Insulin (OI) in Relatives at High Risk for Type 1 Diabetes (T1D)

Diabetes ◽

10.2337/db20-344-or ◽

2020 ◽

Vol 69 (Supplement 1) ◽

pp. 344-OR

Author(s):

JAY SOSENKO ◽

JERRY P. PALMER ◽

MICHAEL J. HALLER ◽

JAY S. SKYLER ◽

ALBERTO PUGLIESE ◽

...

Keyword(s):

Type 1 Diabetes ◽

High Risk ◽

Oral Insulin

Download Full-text

270-OR: Nocturnal Hypoglycemia with Insulin Degludec and Glargine U100 in Patients with Type 1 Diabetes Prone to Severe Nocturnal Hypoglycemia (HypoDeg): A CGM Substudy

Diabetes ◽

10.2337/db20-270-or ◽

2020 ◽

Vol 69 (Supplement 1) ◽

pp. 270-OR

Author(s):

JULIE M. BRØSEN ◽

RIKKE M. AGESEN ◽

AMRA CIRIC ALIBEGOVIC ◽

HENRIK U. ANDERSEN ◽

PETER GUSTENHOFF ◽

...

Keyword(s):

Type 1 Diabetes ◽

Insulin Degludec ◽

Nocturnal Hypoglycemia

Download Full-text

269-OR: Effect of Insulin Degludec on Frequency of Severe Hypoglycemia in Patients with Type 1 Diabetes Prone to Nocturnal Severe Hypoglycemia: The HypoDeg Trial

Diabetes ◽

10.2337/db20-269-or ◽

2020 ◽

Vol 69 (Supplement 1) ◽

pp. 269-OR

Author(s):

RIKKE M. AGESEN ◽

AMRA CIRIC ALIBEGOVIC ◽

HENRIK U. ANDERSEN ◽

PETER GUSTENHOFF ◽

TROELS K. HANSEN ◽

...

Keyword(s):

Type 1 Diabetes ◽

Severe Hypoglycemia ◽

Insulin Degludec

Download Full-text

Social Determinants of Health, Goals and Outcomes in High-Risk Children with Type 1 Diabetes

Canadian Journal of Diabetes ◽

10.1016/j.jcjd.2021.02.005 ◽

2021 ◽

Author(s):

J.A. Hershey ◽

J. Morone ◽

T.H. Lipman ◽

C.P. Hawkes

Keyword(s):

Type 1 Diabetes ◽

High Risk ◽

Social Determinants Of Health ◽

Social Determinants ◽

Determinants Of Health ◽

Health Goals ◽

High Risk Children

Download Full-text

Acylated-based long-acting insulin analogues: Is “misfolding” the problem? Commentary letter on Hamasaki H and Yanai H. The switching from insulin glargine to insulin degludec reduced HbA1c, daily insulin doses and anti-insulin antibody in anti-insulin antibody-positive subjects with type 1 diabetes

Diabetes & Metabolism ◽

10.1016/j.diabet.2014.10.001 ◽

2014 ◽

Vol 40 (6) ◽

pp. 483-484 ◽

Cited By ~ 1

Author(s):

L. Monnier ◽

C. Colette ◽

D. Owens

Keyword(s):

Type 1 Diabetes ◽

Insulin Glargine ◽

Insulin Analogues ◽

Insulin Degludec ◽

Insulin Antibody ◽

Daily Insulin ◽

Acting Insulin ◽

Long Acting

Download Full-text